A randomized placebo-controlled multi-dose Phase IIa trial for PRS-080 in FID anemia patients
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs PRS 080 (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- 09 Aug 2017 According to a Pharmaceuticals media release, the company is planning filing of separate clinical trial applications with the German and Czech Republic regulatory authorities to conduct this trial during this quarter.
- 09 Jul 2017 New trial record
- 05 Jul 2017 The company expects to enroll patients in this trial in the third quarter of 2017 according to a Pieris Pharmaceuticals media release.